Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Supply Chain

Supply Chain of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 28, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

Shenzhen Neptunus Bioengineering Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Shandong Wohua Pharm
Supplier·Pharmaceuticals·CN
0.40
0.92
0.55
0.30
0.27
0.87
2
Shenzhen Neptunus H
Supplier·Customer·Pharmaceuticals·HK
0.52
0.55
0.22
-0.29
-0.49
0.51
#NameTrend
1
Xinlun New Materials A
Supplier·Commercial Services & Supplies·CN
-0.21
0.48
0.16
-0.48
-0.54
-0.01

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

All Key Metrics — Shenzhen Neptunus Bioengineering Co